Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis.

Sudhindra Pudur
Tarak Srivastava
Children's Mercy Hospital
Mukut Sharma
Ram Sharma
Sergey Tarima

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Nephrology Commons

Recommended Citation
Pudur, S., Srivastava, T., Sharma, M., Sharma, R., Tarima, S., Dai, H., McCarthy, E. T., Savin, V. J. Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis. Springerplus 5, 432-432 (2016).

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Creator(s)
Sudhindra Pudur, Tarak Srivastava, Mukut Sharma, Ram Sharma, Sergey Tarima, Hongying Dai, Ellen T. McCarthy, and Virginia J. Savin
Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis

Sudhindra Pudur1, Tarak Srivastava2*, Mukut Sharma3, Ram Sharma3, Sergey Tarima4, Hongying Dai2, Ellen T. McCarthy5 and Virginia J. Savin3

Abstract

Background: Focal segmental glomerulosclerosis (FSGS) is a major cause of renal failure. Sera of some FSGS patients increase glomerular albumin permeability (P_{alb}) during in vitro testing and cause proteinuria in experimental animals.

Objectives: To determine whether permeability activity of FSGS serum (P_{alb} activity) is associated with rate of progression to renal replacement therapy (RRT).

Design: This is an observational study based on medical and demographic information and P_{alb} activity testing.

Setting: Studies were performed at Medical College of Wisconsin.

Patients: Serum was submitted by patients’ nephrologists for measurement of P_{alb} activity. Each patient had had a biopsy diagnosis of FSGS, had reached ESRD and was on dialysis or had a functioning transplant.

Measurements: P_{alb} activity, clinical characteristics and time between biopsy diagnosis and RRT (T-RRT) were recorded for each patient.

Methods: P_{alb} activity was measured using established in vitro techniques.

Results: P_{alb} and T-RRT were inversely correlated. Neither P_{alb} nor T-RRT varied with demographics or medications. Kaplan–Meier survival curves showed that patients with P_{alb} ≥ 0.5 progressed to RRT more rapidly than others.

Limitations: Only patients who had reached RRT were included. Limited clinical information was available for each patient. Central verification of biopsy characteristics was not performed and detailed descriptions of renal histology were not available.

Conclusions: P_{alb} activity is associated with the rate of progression to RRT in patients with FSGS. Additional observations will be needed to verify that P_{alb} activity predicts prognosis and is useful in stratifying patients for clinical decision making or treatment trials.

Keywords: Permeability activity, Focal segmental glomerulosclerosis, Renal replacement therapy

Background

Focal segmental glomerulosclerosis (FSGS) is characterized by nephrotic-range proteinuria and a distinctive histopathological appearance on biopsy. FSGS accounts for a third of primary nephrotic syndrome in adults and a quarter in children. The etiology of FSGS is unknown in the majority of cases, but can be secondary to genetic abnormalities, decreased nephron number, hyperperfusion/hyperfiltration, reflux nephropathy, obesity, viral infections, drugs and malignancy (Daskalakis and Winn).
The lesion in FSGS is progressive and leads to a need for renal replacement therapy (RRT) in 50–75% of patients over a 10-year period (Braun et al. 2008; Korbet 2012; Franceschini et al. 2003; Burgess 1999). In a subset of patients with FSGS, the progression to RRT is rapid and progression to end-stage renal disease occurs within 3 years. A measure by which one could identify patients who are at high risk for rapid progression to RRT would allow modification of the approach to therapy for the individual patient. In addition, a tool to identify these subjects would be valuable in designing and interpreting clinical trials on FSGS.

We have developed albumin permeability ($P_{\text{alb}}$) testing as a functional assay to provide a sensitive measure of the integrity of the glomerular macromolecular permeability barrier. Experimental values for $P_{\text{alb}}$ activity vary from 0, normal, to 1.0, representing maximal loss of barrier function (Savin et al. 1992). We have used this test to determine the effect of patient serum on glomerular barrier function. We have shown increased permeability activity ($P_{\text{alb}}$ activity or $P_{\text{alb}}^*$) in samples of serum or plasma from renal transplant recipients with recurrent FSGS (Catran et al. 2003; Savin et al. 2008). $P_{\text{alb}}$ activity is stable over time (Catran et al. 2003; Savin et al. 1996, 2008) and is not affected by treatment with cyclosporine even when there is remission of nephrotic syndrome and is diminished by plasmapheresis (Savin et al. 1996). The injurious effect of serum as well as the occurrence of proteinuria in experimental animals after injection of serum, plasma or plasma fractions, and remission of post-transplant proteinuria after plasmapheresis or immunoabsorption has led us to hypothesize that a circulating factor is responsible for recurrence of FSGS in allografts (Savin et al. 1996; Sharma et al. 2002, 2004a, b; McCarthy et al. 2010; Zimmerman 1984). The aim of the current study was to determine if high $P_{\text{alb}}$ activity in patients with FSGS is associated with rapid progression to RRT in native kidneys.

**Methods**

**Patient samples**

Albumin permeability ($P_{\text{alb}}$) activity was determined using serum samples submitted to the Center for Glomerular Pathophysiology at the Medical College of Wisconsin in the course of clinical evaluation of FSGS. All research activities were approved by the Human Subjects Committee of the Medical College of Wisconsin and were in compliance with the Helsinki Declaration. Samples were frozen at the site of collection and shipped to the study site by overnight carrier and remained frozen until they were thawed for analyses. Samples submitted from January 2001 through December 2004 were included. Inclusion criteria were diagnosis of primary FSGS as indicated on renal biopsy report, progression to renal replacement therapy (RRT) and availability of data including patient demographics, laboratory data, renal biopsy diagnosis, date of renal biopsy, date of initiation of dialysis or transplant and medications prescribed at the time the serum specimen was collected. Data regarding the duration of symptoms and information about medical therapy given prior to serum sample collection were not available. Patients with incomplete data and those who had not progressed to RRT were excluded. Values from samples obtained after plasmapheresis therapy were excluded because we have shown that this therapy decreases $P_{\text{alb}}$ activity (Savin et al. 1996). No information regarding renal function at the time of the biopsy, reason for performing the biopsy, details of renal histology, or classification of the pattern of FSGS was available. Time to renal replacement therapy (T-RRT) was defined as the duration between the date of biopsy diagnosis of FSGS to one of the following: (a) the date of initiation of dialysis, (b) the date of renal transplantation or (c) the date when GFR was <15 ml/min as estimated by MDRD formula for adults and Schwartz formula for children. Rapid progression was defined as the progression to RRT within 3 years of diagnosis. This cut-off was chosen because it is commonly used in the pediatric literature as a parameter associated with high risk for post-transplant recurrence (Artero et al. 1994).

**Albumin permeability ($P_{\text{alb}}$) assay**

$P_{\text{alb}}$ is a continuous dimensionless variable that ranges from 0 to 1. $P_{\text{alb}}$ testing was carried out under standard conditions (Savin et al. 1992, 1996). Briefly, glomeruli were isolated from the renal cortex of normal rats. Isolation/incubation medium was isotonic and contained bovine albumin, 5 gm/dl, as an oncotic agent. Glomeruli were incubated for 10 min at 37 °C in medium to which patient serum, 2 % vol/vol, had been added or in control medium. $P_{\text{alb}}$ was calculated as previously described (Sharma et al. 2000). In the current study, $P_{\text{alb}}$ activity of ≥0.5 was used to define high activity. This cutoff value is consistent with our practice for interpretation of values for individual patients and is the 95 % confidence limit for values from normal serum or sera of patients with non-glomerular disease (Savin et al. 1996). We performed additional analyses in which patients were stratified using $P_{\text{alb}}$ activity of ≥0.4 to ≥0.7. All measurements were carried out without knowledge of the sample being tested and both positive and negative control samples were tested in each assay.

**Statistical analyses**

Continuous variables were summarized as mean ± SD. Univariate correlations were evaluated using Pearson
correlation analysis. Group comparisons were performed using Student’s *t* test. The Chi squared test was used to investigate changes in proportion of categorical variables. Odds ratio was used to measure the association of \( P_{\text{ab}} \) with T-RRT. Renal survival was investigated using Kaplan–Meier survival curves stratified by time compared between groups using the log-rank test. In addition, a latent class regression model was fitted to the data to detect heterogeneity of associations between \( P_{\text{ab}} \) and T-RRT. Statistical analysis was performed using SPSS 20.0 software (SPSS Inc., Chicago, IL) and SAS version 9.1(SAS Institute Inc., Cary, NC). A p-value of <0.05 was considered statistically significant.

Results

Patient characteristics

A total of 103 serum samples were submitted during the period studied. Of these, 87 were from patients with FSGS. The others were from patients in whom no biopsy report was available or who had other proteinuric renal diseases. Complete data was available for 80 samples; these were included in further analysis. \( P_{\text{ab}} \) activity averaged 0.58 \( \pm \) 0.25 (mean \( \pm \) SD, \( n = 80 \), range 0.05–0.98) with a median of 0.52. Patients’ age ranged from 1 to 63 years; 35 (44%) were male, 53 (66%) were Caucasian, 21 (26%) were African-American, 5 (6%) were Hispanic and 1 (1%) Asian. Average T-RRT was 3.2 \( \pm \) 3.3 years (\( n = 80 \), range 0–14.5 years). At the time of sample collection, 25% were receiving angiotensin converting enzyme inhibitors (ACE-I), 11% angiotensin receptor blockers (ARB) and 16% statin therapy (Table 1). Sixteen percent were receiving steroids, 5% cyclosporine.

Eighteen patients had been transplanted, 6 had experienced recurrence and 4 had lost allografts. Seven of the transplanted patients were not on immunosuppression at the time of the sample; each of these patients had failing allografts or had lost prior allografts. All patients who experienced FSGS recurrence had \( P_{\text{ab}} \) activity \( \geq 0.5 \).

Relationships between \( P_{\text{ab}} \) activity and T-RRT in FSGS

Forty-six patients (57.5 %) required RRT within 3 years after renal biopsy. \( P_{\text{ab}} \) activity in these patients was significantly higher than in patients who had a longer course to RRT (0.63 \( \pm \) 0.22 vs. 0.50 \( \pm \) 0.28, \( p = 0.025 \)). In patients with T-RRT > 3 months, there was a significant inverse correlation between \( P_{\text{ab}} \) activity and T-RRT described by the equation T-RRT = 7.10 – 4.96\( P_{\text{ab}} \) (Pearson correlation coefficient \( r = -0.27 \), \( p = 0.016 \)). \( P_{\text{ab}} \) activity was the only significant predictor for T-RRT. There was no effect of age, gender or ethnicity (proportional hazards model). The frequency distribution of \( P_{\text{ab}} \) activity \( \geq 0.5 \) and T-RRT was calculated in order to further examine the association between \( P_{\text{ab}} \) activity and T-RRT. Results are shown in Fig. 1. Associations were as follows: Thirty-seven patients had T-RRT < 3 years and \( P_{\text{ab}} \geq 0.5 \), 9 had T-RRT < 3 years and \( P_{\text{ab}} < 0.5 \), 18 had T-RRT \( \geq 3 \) years and \( P_{\text{ab}} \geq 0.5 \) and 16 had T-RRT \( \geq 3 \) years and \( P_{\text{ab}} < 0.5 \). The odds ratio was calculated for T-RRT < 3 years in patients with \( P_{\text{ab}} \) activity \( \geq 0.5 \) was 3.65 (95% CI of 1.36–9.86). Chi square test showed a significant difference on T-RRT < 3 years between low and high \( P_{\text{ab}} \) activity groups (36.0 vs. 67.3%, respectively, \( p = 0.009 \)). There were no significant differences in \( P_{\text{ab}} \) between Caucasians and African-Americans.

### Table 1 Patient characteristics

| Number of patients in each category is as indicated. Percentages are calculated according to the number in each \( P_{\text{ab}} \) or T-RRT category and there were no statistically significant differences between patients with \( P_{\text{ab}} < 0.5 \) and those with higher values nor were there differences between those with T-RRT < 3 years and those with a longer course. | All patients | Stratified by \( P_{\text{ab}} \) | Stratified by T-RRT |
|---|---|---|---|
| **Number** | 80 | \( P_{\text{ab}} < 0.5 \) 25 | \( P_{\text{ab}} \geq 0.5 \) 55 |
| **Age (years)** | 30.1 ± 17.2 | 29.7 ± 19.6 | 30.2 ± 16.2 |
| **Male gender, n (%)** | 35 (44) | 10 (40) | 25 (45) |
| **Ethnicity, n (%)** | | | |
| Caucasian | 53 (66) | 17 (68) | 36 (65) |
| African American | 21 (26) | 6 (24) | 15 (27) |
| Other | 7 (9) | 2 (8) | 5 (9) |
| **Medications, n (%)** | | | |
| ACEI and/o ARB | 25 (31) | 7 (28) | 18 (33) |
| Steroids | 13 (16) | 1 (4) | 12 (21) |
| Cyclosporine or tacrolimus | 4 (5) | 1 (4) | 3 (5) |
| Statins | 13 (16) | 3 (12) | 10 (18) |
| | | | 9 (20) |
| | | | 4 (11) |
Palb activity did not vary significantly with medications, age, gender or ethnicity as covariates in a linear regression model. Kaplan–Meier survival curves showed that patients who had $P_{\text{alb}} \geq 0.5$ progressed to renal replacement therapy more rapidly than others by log rank (Mantel–Cox) test ($p = 0.009$). The Kaplan–Meier curves displayed here were generated using only samples from patients ($n = 66$) in whom T-RRT was >3 months (Fig. 2). This decision was made on the basis of the latent class regression model described below. Note that the survival diverged after 1 year and that by 4 years, survival was more than double in the group with low $P_{\text{alb}}$ activity versus those with high $P_{\text{alb}}$ activity. Differences in the Kaplan–Meier survival curves were also significant for $P_{\text{alb}} \geq 0.4$ ($p = 0.01$) and $P_{\text{alb}} \geq 0.6$ ($p = 0.012$), but not for a $P_{\text{alb}}$ activity cut-off $\geq 0.7$ (data not shown). Thus, $P_{\text{alb}}$ activity discriminated between patients with FSGS who did or did not have T-RRT within 3 years.

At a cut-off for $P_{\text{alb}}$ activity of $\geq 0.5$, the sensitivity and specificity were 80.4 and 47.1 %, respectively. The positive and negative predictive values were 67.3 and 64.0 %, respectively.

**Latent class regression model**

A latent class regression model for associations between $P_{\text{alb}}$ and T-RRT was applied and 2 distinct patterns were identified. In 14 patients, T-RRT was $\leq 3$ months. These patients with calculated T-RRT $< 3$ months (0.25 years) were excluded from this analysis (see text in “Results” section, “latent class regression model” for the rationale for this exclusion).
patients had advanced CKD at the time of biopsy as indicated by high serum creatinine. \( P_{\text{alb}} \) activity was not significantly associated with T-RRT. In the remaining 66 subjects, in whom biopsies showing FSGS were performed when the GFR was higher, there was an inverse association between \( P_{\text{alb}} \) and T-RRT described by the fitted regression equation, \( T\text{-RRT} = 7.10 - 4.96\times P_{\text{alb}} \).

**Discussion**

The clinical course in adults with primary FSGS is variable, with about half of adults progressing to RRT in 10 years (Braun et al. 2008; Korbet 2012; Franceschini et al. 2003; Burgess 1999). Currently, there is no good historical or biochemical marker that predicts outcome in FSGS. Histological variants have been described and attempts have been made to use histological classification to predict response to therapy and prognosis (Schwartz et al. 1999; Thomas et al. 2006; Chun et al. 2004; Barisoni 2012). The collapsing variant shows a more rapid progression compared to other histological classes but other histological variants including tip lesion do not predict either response to treatment or prognosis (Valeri et al. 1996; Detwiler et al. 1994; Couser 2005). The treatment of primary FSGS is based on the rationale that a humoral factor or factors derived from a dysregulated immune system are responsible for development of proteinuria. At present, the majority of therapeutic interventions depends on corticosteroids or other traditional immunosuppressive agents and is associated with a range of side-effects (Braun et al. 2008; Korbet 2012). Recent studies indicate that cyclosporine and mycophenolate mofetil each induce remission in some steroid resistant patients (Hogg et al. 2013). Other novel agents including adalimumab (anti-TNF alpha), galactose and a novel dual endothelin receptor blocker and angiotensin receptor blocker (DUET trial, Sparasant) are in trials (Joy et al. 2010; Trachtman et al. 2011a, b, 2015). A biomarker that could be used to stratify FSGS patients according to risk for rapid progression would be useful in design and interpretation of such trials. Such a biomarker might eventually allow individualization of therapy according to the potential risks and benefit.

Strengths of this study include the fact that our unique sample included FSGS patients who had reached RRT at the time of testing for \( P_{\text{alb}} \). All FSGS patients whose samples we analyzed were included; there were no censored observations. Patients represented a wide range of rates of progression and included both genders, and included both children and adults as well as several ethnicities. However, the study has several limitations. First, the dataset was limited to a cohort of FSGS patients who had progressed to RRT. We did not include samples from patients who continued to have adequate GFRs at the time the sample was submitted. We had only limited information regarding the patients’ prior history. Our information regarding medications was limited to their current therapy at the time of serum sample. We collected the information regarding current medications to examine potential interference with the \( P_{\text{alb}} \) activity assay. No other information about their treatment during the course of disease was available but it is likely that many patients had received corticosteroids. The low rates of immunosuppressive therapy may have reflected the fact that the majority had reached ESRD and were no longer on therapy directed at treatment of FSGS or nephrotic syndrome while others may never have received therapy. The small size of the sample does not permit analysis of potential medication effects but our prior work indicates that cyclosporine does not alter \( P_{\text{alb}} \) (Catran et al. 2003).

An additional limitation arises from the fact that the sample may reflect referral bias as it relates to submission of the sample for \( P_{\text{alb}} \) testing. The sample may include a disproportionate number of patients who had good access to health care and to physicians who were aware of the potential for \( P_{\text{alb}} \) testing. It may also over-represent patients with prior post-transplant recurrence or those who are awaiting initial renal transplants.

We have used \( P_{\text{alb}} \) to follow activity of plasma during sequential fractionation and to characterize the circulating permeability factor for recurrence of FSGS in allografts. The central role for a circulating permeability factor in FSGS is based on the observations of (a) early recurrence of nephrotic syndrome after transplantation, (b) development of albuminuria in rats after injection of serum from these patients, (c) response to plasma exchange and (d) occurrence of transient proteinuria in infants born to women with FSGS (Savin et al. 1996; Sharma et al. 2002, 2004a, b; McCarthy et al. 2010; Zimmerman 1984; Gohh et al. 2005; Kemper et al. 2001). We have described the circulating permeability factor as a hydrophobic sialoprotein with a molecular weight in the range of 30 kDa. It binds to galactose coated agarose beads and can be eluted using a galactose solution (Sharma et al. 2004a). We have used mass spectrometry to identify cardiotoxophilic-like cytokine factor-1 (CLCF-1) in active fractions and have shown that glomerular and podocyte responses to CLCF-1 parallel the responses to FSGS serum (McCarthy et al. 2010; Sharma et al. 2015). Another candidate for the FSGS “factor” has been identified by Wei and colleagues. They have reported that increased concentrations of soluble urokinase-type plasminogen activator receptor (suPAR) are present in FSGS plasma and propose that suPAR concentration predicts post-transplant recurrence (Wei et al. 2011). Additional molecules including hemopexin, angiopoietin-like-4 and CD80 are associated with nephrotic syndrome and have...
also been shown to cause proteinuria in experimental animals (Garin et al. 2010; Lennon et al. 2008; Clement et al. 2011) but do not appear to be relevant to FSGS. The severity of nephrotic syndrome or FSGS is generally classified as "steroid sensitive," "steroid resistant" or "steroid dependent" and according to the response to cytotoxic or immunosuppressive agents. These categories are necessarily applied only post hoc and cannot be used to guide initial treatment. Likewise, even within categories defined by response to therapy, there is no clear association between clinical parameters and progression of renal failure. There are no reports of a quantitative method for stratifying risk of rapid progression to RRT.

We have proposed that $P_{\text{alb}}$ activity $\geq 0.5$ reflects the presence of a high concentration of circulating permeability factor(s) which causes significant glomerular injury and rapid progression in FSGS. $P_{\text{alb}}$ activity was $>0.5$ in 38% of 26 children with newly diagnosed nephrotic syndrome 2 of whom were later diagnosed with FSGS. In that sample, $P_{\text{alb}}$ but did not differ between steroid sensitive and steroid resistant patients (Trachtman et al. 2004). We have found $P_{\text{alb}}$ activity $\geq 0.5$ in 20–38% in additional cohorts of FSGS (Savin et al. 1996; Trachtman et al. 2004). We previously reported that patients in whom FSGS recurred after transplantation had a higher $P_{\text{alb}}$ (0.47 ± 0.06) compared to that of FSGS patients who did not recur (0.14 ± 0.06). A $P_{\text{alb}}$ value of 0.5 permitted risk stratification, with 86% of patients with $P_{\text{alb}}$ value of $\geq 0.5$ developing recurrence versus only 17% with $P_{\text{alb}} < 0.5$ (Savin et al. 1996). In an independent sample of patients awaiting transplantation, $P_{\text{alb}}$ was greater than 0.6 in 9 of 10 patients with prior recurrence or rapid progression to ESRD (mean $P_{\text{alb}}$ 0.76 ± 0.21, n = 10) (Gohh et al. 2005). Testing $P_{\text{alb}}$ activity is currently available on a limited scale in our laboratory. It may provide an opportunity to evaluate FSGS patients using a non-invasive test. Measurement of a single molecule in the circulation may eventually supplant this functional assay, but the identity of active molecules in FSGS is currently being studied and may eventually identify injurious molecule. The $P_{\text{alb}}$ assay may eventually be used to design and interpret clinical research trials on FSGS. Prospective validation of our findings in a trial with defined selection criteria will be required prior to the general use of $P_{\text{alb}}$ activity for establishing prognosis in patients with FSGS.

In summary, our results indicate that high $P_{\text{alb}}$ activity is associated with rapid progression to RRT in biopsy proven FSGS. We suggest that $P_{\text{alb}}$ activity may be useful for risk stratification in future clinical trials of aggressive therapy or novel therapy in FSGS. Further studies will be required before $P_{\text{alb}}$ activity can be used to provide specific prognosis or dictate therapy in individual patients.

References
Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23(4):574–581
Barisoni L (2012) Podocyte biology in segmental sclerosis and progressive glomerular injury. Adv Chronic Kidney Dis 19(2):76–83
Braun N, Schwitzer F, Lange C et al (2008) Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 3:CD003233
Burgess E (1999) Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int 55:526–532
Cartrán D, Neogi T, Sharma R, McCarthy ET, Savin VJ (2003) Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 14(2):448–453
Chun M, Korbet S, Schwartz M, Lewis EJ (2004) Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15:2169–2177
Clement LC, Avila-Casado C, Maïé C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephritic syndrome. Nat Med 17(1):117–122
Couper W (2005) Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp Clin Transplant 3(1):283–288
D’Agati VD, Kaskel FJ, Falk RJ (2011) Focal segmental glomerulosclerosis. N Engl J Med 365(25):2398–2411
Daskalakis N, Wynn MP (2006) Focal and segmental glomerulosclerosis: varying biological mechanisms underlie a final histopathologic end point. Semin Nephrol 26:89–94
Dettwiler RK, Falk RJ, Hogan SL, Jennette JC (1994) Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 45:1416–1424
Franceschini N, Hogan SL, Falk RJ (2003) Primus non nocere: should adults with idiopathic FSGS receive steroids? Sem Nephrol 23:229–233
Garin EH, Mu W, Arthur JM et al (2010) Urinary CDBS is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78(3):296–302

Authors’ contributions
The roles of the authors are as follows: SP designed the study, carried out data collection and analysis and wrote the initial manuscript. TS and HD performed statistical analyses. TS provided additional analyses and major revisions of the manuscript. MS performed all $P_{\text{alb}}$ analyses and directed the study design. RS, ETM and VIS participated in study design and review and revisions of the manuscript. All authors read and approved the final manuscript.

Author details
1 Renal Hypertension Center, Hudson, FL, USA. 2 Section of Nephrology, Children’s Mercy Hospital, University of Missouri at Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA. 3 Kansas City Veterans Hospital, Kansas City, MO, USA. 4 Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. 5 Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA.

Acknowledgements
The study was supported in by NIH Grants R01 DK 43752 and DK R21 00292588 (Savin), DK R01 DK64969 (McCarthy) and from the VA BX001037 (Savin) and funds from the Midwest Biomedical Research Foundation (Savin, Sharma). This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

Competing interests
The authors declare that they have no competing interests.

Received: 13 January 2016 Accepted: 30 March 2016
Published online: 11 April 2016
Gohh RY, Yang AF, Morrissey PE et al (2005) Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5(12):2907–2912
Hogg RJ, Friedman A, Greene T et al (2013) Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. Clin J Am Soc Nephrol 8(2):211–218
Joy MS, Gipson DS, Powell L et al (2010) Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 55(1):50–60
Kemper MJ, Wolf G, Müller-Wiefel DE (2001) Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 344(5):386–387
Korbet SM (2012) Treatment of primary FSGS in adults. J Am Soc Nephrol 23(11):1769–1776
Lennon R, Singh A, Welsh GI et al (2008) Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol 19(11):2140–2149
McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5(11):2115–2121
Savin VJ, Sharma R, Lovell HB, Welling DJ (1992) Measurement of albumin reflection coefficient in isolated rat glomeruli. J Am Soc Nephrol 3:1260–1269
Savin VJ, Sharma R, Sharma M et al (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883
Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151:288–292
Schwartz MM, Evans J, Bans R, Korbet SM (1999) Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 10:1900–1907
Sharma R, Sharma M, McCarthy ET, Ge XL, Savin VJ (2000) Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 58:1973–1979
Sharma M, Sharma R, Reddy SR, McCarthy ET, Savin VJ (2002) Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 73:366–372
Sharma M, Sharma R, McCarthy ET, Savin VJ (2004a) The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med (Maywood) 229(1):85–98
Sharma R, Sharma M, Savin VJ, McCarthy ET (2004b) The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 229:85–98
Sharma M, Zhou J, Gauchat JF, Sharma R, McCarthy ET, Srivastava T, Savin VJ (2015) Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiophrin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res 166(4):384–398
Thomas DB, Franceschini N, Hogan SL et al (2006) Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 69:920–926
Trachtman H, Greenbaum LA, McCarthy ET et al (2004) Glomerular permeability activity: prevalence and prognostic value in pediatric patients with idiopathic nephrotic syndrome. Am J Kidney Dis 44:604–610
Trachtman H, Vento S, Gipson D et al (2011a) Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 12:8
Trachtman H, Fervenza FC, Gipson DS et al (2011b) A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79(11):1236–1243
Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS (2015) Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the Font clinical trial group. BMC Nephrol 16:111
Valeri A, Bansoni L, Appel GB, Seigle R, D’Agati V (1996) Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 50:1734–1746
Wei C, El Hindi S, Li J et al (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17(8):952–960
Zimmerman SW (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22:32–38

Submit your manuscript to a SpringerOpen journal and benefit from:
► Convenient online submission
► Rigorous peer review
► Immediate publication on acceptance
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com